Last updated: December 25, 2023
Sponsor: Xuanwu Hospital, Beijing
Overall Status: Active - Recruiting
Phase
N/A
Condition
Stroke
Cardiac Ischemia
Blood Clots
Treatment
Standard Medical Treatment on the basis of anti-platelet therapy
Clinical Study ID
NCT06196398
XWFFR-3
Ages 30-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients aged from 30 to 80 with symptomatic ICAS lesion in anterior circulation.
- 50% to 99% stenosis (in accordance with modified WASID method) confirmed by DSA, CTAor MRA.
- mRS 0-2 points
- Informed of the study protocol and objectives.
Exclusion
Exclusion Criteria:
- Previous endovascular treatment or surgery for cerebrovascular diseases
- Large cerebral infarction (more than 1/2 MCA perfusion area) according to MRI
- Combined with other neurological diseases, such as aneurysm, arteriovenousmalformation, tumor, hydrocephalus, cerebral trauma, cerebral hemorrhage, multiplesclerosis, epilepsy and intracranial infection.
- Pregnancy or in the preparation for pregnancy
- Patients who cannot tolerate or do not allow MR screening, including metal implantingand claustrophobia
- Contraindication for antiplatelet drugs or statins
- Patients with severe dementia or mental disorders, who cannot cooperate withexamination
Study Design
Total Participants: 400
Treatment Group(s): 1
Primary Treatment: Standard Medical Treatment on the basis of anti-platelet therapy
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
June 30, 2024
Connect with a study center
Xuanwu Hospital, Capital Medical University
Beijing, Beijing
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.